metastatic breast cancer

Research Reports

Potential Cost Effectiveness of FES-PET to Determine Estrogen Receptor Status in Metastatic Breast Cancer in the United States

10/20/2021

Hannah M. Linden , MD;

Poorni M. Manohar , MD;

Josh A. Roth , PhD, MHA;

Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.

Poorni M. Manohar, MD, et al...

10/20/2021

Journal of Clinical Pathways

Research Reports

Effectiveness of Eribulin in Metastatic Breast Cancer Patients With Poor Prognostic Indicators in the United States

06/21/2021

Bruce A. Feinberg , DO;

Talia Miller , MSW, MPH;

Jingchuan Zhang , PhD;

Marjorie E. Zettler , PhD, MPH;

Sarah S. Mougalian , MD;

A retrospective real-world study demonstrates the clinical effectiveness of eribulin in subgroups of MBC patients with poor prognostic characteristics, when used in accordance with the approved US indication.

A retrospective real-world study...

06/21/2021

Journal of Clinical Pathways